Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit

Rhea-AI Summary

Design Therapeutics, Inc. (Nasdaq: DSGN) announced that its CEO, João Siffert, M.D., and COO, Sean Jeffries, Ph.D., will participate in a fireside chat at the 2022 Jefferies Cell and Genetic Medicine Summit on September 29, 2022, at 10:00 a.m. ET in NYC. A live webcast will be available on the investor section of the company's website and archived for 30 days. Design Therapeutics focuses on developing innovative therapies using its GeneTAC™ platform to treat degenerative genetic diseases, with lead programs targeting Friedreich ataxia and myotonic dystrophy type-1.

CARLSBAD, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported that João Siffert, M.D., president and chief executive officer, and Sean Jeffries, Ph.D., chief operating officer, will participate in a fireside chat during the 2022 Jefferies Cell and Genetic Medicine Summit on Thursday, September 29, 2022, at 10:00 a.m. ET in NYC.

A live webcast will be available in the investor section of the company's website at www.designtx.com and will be archived for 30 days following the presentation.

About Design Therapeutics
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC™ gene targeted chimera small molecules. The company’s GeneTAC™ molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. Design’s lead program is focused on the treatment of Friedreich ataxia, followed by a program in myotonic dystrophy type-1 and discovery efforts for multiple other serious degenerative disorders caused by nucleotide repeat expansions. For more information, please visit designtx.com.

Contact:
Investors:
Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com 

FAQ

What is the event Design Therapeutics is participating in on September 29, 2022?

Design Therapeutics will participate in the 2022 Jefferies Cell and Genetic Medicine Summit on September 29, 2022.

Who will represent Design Therapeutics at the Jefferies Summit?

João Siffert, M.D., and Sean Jeffries, Ph.D., will represent Design Therapeutics at the summit.

How can I watch the Design Therapeutics presentation at the Jefferies Summit?

The presentation will be available via live webcast on Design Therapeutics' investor website and archived for 30 days.

What are the main focus areas of Design Therapeutics?

Design Therapeutics focuses on developing therapies for serious degenerative genetic diseases, particularly Friedreich ataxia and myotonic dystrophy type-1.

What platform does Design Therapeutics use for its therapies?

Design Therapeutics uses its GeneTAC™ platform to develop therapies targeting disease-causing genes.